株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

慢性冠動脈疾患(CAD)(虚血性心疾患) : パイプライン製品の分析

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 321903
出版日 ページ情報 英文 202 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.08円で換算しております。
Back to Top
慢性冠動脈疾患(CAD)(虚血性心疾患) : パイプライン製品の分析 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2017
出版日: 2017年07月25日 ページ情報: 英文 202 Pages
概要

慢性冠動脈疾患(CAD)は、最も一般的な種類の心疾患です。コレステロール等、プラークと呼ばれる物質が心筋に血液を送る冠動脈内壁に堆積し、硬化・狭窄することによって起こります。最も多い症状は狭心症、胸痛であり、その他息切れ、動悸、頻脈、めまい、悪心、発汗などが現れる場合があります。

当レポートでは、慢性冠動脈疾患(CAD)(虚血性心疾患)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

慢性冠動脈疾患(CAD)(虚血性心疾患)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:企業別
  • パイプライン製品:大学/研究機関別
  • 開発中の製品:企業別
  • 開発中の製品:大学/研究機関別

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬の開発に従事している企業

  • Amarantus Bioscience Holdings Inc
  • AnGes MG Inc
  • Angionetics Inc
  • Ascendia Pharmaceuticals LLC
  • AstraZeneca Plc
  • Athera Biotechnologies AB
  • Bayer AG
  • Biscayne Pharmaceuticals Inc
  • Capricor Therapeutics Inc
  • CardioVascular BioTherapeutics Inc
  • CSL Ltd
  • Gilead Sciences Inc
  • Human Stem Cells Institute
  • Idorsia Ltd
  • Juventas Therapeutics Inc
  • Lee's Pharmaceutical Holdings Ltd
  • LipimetiX Development Inc
  • Livzon Pharmaceutical Group Inc
  • Lonestar Heart Inc
  • MedImmune LLC
  • Merck & Co Inc
  • Nuo Therapeutics Inc
  • Pfizer Inc
  • Proteon Therapeutics Inc
  • Resverlogix Corp
  • Tasly Pharmaceutical Group Co Ltd
  • The Medicines Company
  • Verseon Corp
  • VESSL Therapeutics Ltd
  • ViroMed Co Ltd
  • XyloCor Therapeutics Inc

薬剤のプロファイル

開発休止中のプロジェクト

開発が中止された製品

開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9575IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2017, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.

Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 4, 15, 8, 1, 18 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview
    • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development
    • Amarantus Bioscience Holdings Inc
    • AnGes MG Inc
    • Angionetics Inc
    • Ascendia Pharmaceuticals LLC
    • AstraZeneca Plc
    • Athera Biotechnologies AB
    • Bayer AG
    • Biscayne Pharmaceuticals Inc
    • Capricor Therapeutics Inc
    • CardioVascular BioTherapeutics Inc
    • CSL Ltd
    • Gilead Sciences Inc
    • Human Stem Cells Institute
    • Idorsia Ltd
    • Juventas Therapeutics Inc
    • Lee's Pharmaceutical Holdings Ltd
    • LipimetiX Development Inc
    • Livzon Pharmaceutical Group Inc
    • Lonestar Heart Inc
    • MedImmune LLC
    • Merck & Co Inc
    • Nuo Therapeutics Inc
    • Pfizer Inc
    • Proteon Therapeutics Inc
    • Resverlogix Corp
    • Tasly Pharmaceutical Group Co Ltd
    • The Medicines Company
    • Verseon Corp
    • VESSL Therapeutics Ltd
    • ViroMed Co Ltd
    • XyloCor Therapeutics Inc
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles
    • ACT-246475 - Drug Profile
    • AEM-28 - Drug Profile
    • AEM-2802 - Drug Profile
    • ALD-201 - Drug Profile
    • alferminogene tadenovec - Drug Profile
    • alprostadil - Drug Profile
    • AMRS-001 - Drug Profile
    • anacetrapib - Drug Profile
    • apabetalone - Drug Profile
    • APT-402 - Drug Profile
    • AZD-5069 - Drug Profile
    • AZD-5718 - Drug Profile
    • BAT-2094 - Drug Profile
    • beperminogene perplasmid - Drug Profile
    • BIS-5409 - Drug Profile
    • bivalirudin trifluoroacetate - Drug Profile
    • cangrelor tetrasodium - Drug Profile
    • CAP-1002 - Drug Profile
    • CAP-2003 - Drug Profile
    • clopidogrel bisulphate - Drug Profile
    • COR-2 - Drug Profile
    • Cryocell - Drug Profile
    • CSL-112 - Drug Profile
    • CVBT-141H - Drug Profile
    • dalcetrapib - Drug Profile
    • Gemacell - Drug Profile
    • JVS-100 - Drug Profile
    • MEDI-6012 - Drug Profile
    • MultiGeneAngio - Drug Profile
    • MZ-004 - Drug Profile
    • Neovasculgen - Drug Profile
    • PC-mAb - Drug Profile
    • PF-06282999 - Drug Profile
    • PMC-6 - Drug Profile
    • PR-15 - Drug Profile
    • Proteins for Ischemic Heart Disease - Drug Profile
    • ranolazine ER - Drug Profile
    • Recombinant Protein for Cardiovascular Diseases - Drug Profile
    • Rejuveinix - Drug Profile
    • rivaroxaban - Drug Profile
    • Small Molecules for Ischemic Heart Disease - Drug Profile
    • Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile
    • Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile
    • TSL-0202 - Drug Profile
    • vericiguat - Drug Profile
    • VM-202 - Drug Profile
    • vonapanitase - Drug Profile
    • XC-001 - Drug Profile
    • Xcel-hCardP - Drug Profile
    • Xcel-hCM - Drug Profile
    • ZK-001 - Drug Profile
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Angionetics Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Athera Biotechnologies AB, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Capricor Therapeutics Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CSL Ltd, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Idorsia Ltd, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by LipimetiX Development Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Livzon Pharmaceutical Group Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune LLC, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pfizer Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Proteon Therapeutics Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Resverlogix Corp, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Verseon Corp, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by VESSL Therapeutics Ltd, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co Ltd, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by XyloCor Therapeutics Inc, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top